Phase 3
Completed N=130
Long-term Safety Study for GSK573719/GW642444 in Japanese
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT01376388 ↗
Enrolled (actual)
130
Serious AEs
12.3%
Results posted
Mar 2014
Primary outcomePrimary: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period — 113; 16 Participants
Summary
The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily. The product will be delivered via the Novel Dry Powder Inhaler (nDPI) over 52 weeks to Japanese subjects with Chronic Obstructive Pulmonary Disease (COPD). This is a multi-centre, open-label study evaluating the safety of GSK573719/GW642444 Inhalation Powder 125/25 mcg. Treatment will be given once-daily in the morning. The target enrolment is approximately 120 subjects at approximately 20 study centres in Japan. The total duration of subject participation will be 54-55 weeks, consisting of a 7-14 day run-in period, 52-week treatment period and 1-week follow-up period. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at screening visit (Visit 1) will enter 7-14 day run-in period. The run-in period is provided for completion of baseline safety evaluations and to obtain baseline measures of COPD status. At Visit 2, eligible subjects will start to take GSK573719/GW642444 125/25 mcg, and enter the treatment period. This treatment will be delivered via the Novel Dry Powder Inhaler (nDPI) once daily in the morning for 52 weeks. One nDPI will contain 30 doses of study medication. Subjects will be instructed to administer medication once daily in the morning for the duration of the 52-week treatment period. Each subject should be advised to adhere to this dosing regimen throughout the study. There will be a total of 8 study visits including at screening (Visit 1), initiation of treatment (Visit 2), and at 4weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks (Visit 3 through Visit 8, respectively). Follow-up (Visit 9) will be conducted by the phone contact approximately 1 week following the completion/withdrawal of treatment period. A subject will be considered to have completed the study upon completion of the last on-treatment visit (Visit 8). At the end of the treatment period, subjects will be prescribed appropriate COPD medication at the investigator's discretion.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period |
113; 16 | — |
| PRIMARY Number of Participants With AEs Classified by the Indicated Maximum Grade Throughout the Treatment Period |
83; 20; 10 | — |
| SECONDARY Basophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD |
0.54; 0.58; 0.59; 0.60; 0.35; 0.58 | — |
| SECONDARY Eosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD |
0.245; 0.225; 0.260; 0.219; 0.135; 0.254 | — |
| SECONDARY Hemoglobin, Albumin, and Total Protein Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/Withdrawal (WD) |
145.1; 148.2; 148.1; 148.2; 146.6; 148.0 | — |
| SECONDARY Hematocrit Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD |
0.4460; 0.4534; 0.4515; 0.4517; 0.4473; 0.4512 | — |
| SECONDARY Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD |
242.1; 250.2; 257.3; 247.5; 227.7; 254.2 | — |
| SECONDARY Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD |
3.736; 3.514; 3.350; 3.680; 3.249; 3.340 | — |
| SECONDARY Calcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Phosphorous Inorganic, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD |
2.2954; 2.2948; 2.2837; 2.2765; 2.2829; 2.2842 | — |
| SECONDARY Change From Baseline in Blood Pressure |
1.1; 2.0; 2.5; 2.7; -3.3; 0.4 | — |
| SECONDARY Change From Baseline in Heart Rate |
-0.7; -0.7; -1.4; -0.5; -2.2; -0.7 | — |
| SECONDARY Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points |
45; 2; 50; 2; 43; 3 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatient.
- A signed and dated written informed consent prior to study participation.
- Japanese subjects 40 years of age or older at screening.
- Male or female subjects (female subjects who have child bearing potential has a negative pregnancy test at screening, and agrees to one of the acceptable contraceptive methods used consistently and correctly).
- Diagnosis of COPD.
- 10 pack-year or greater history of cigarette smoking.
- Post-bronchodilator FEV1/FVC of <0.7.
- Predicted FEV1 of <80%.
Exclusion Criteria
- Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- A current diagnosis of asthma.
- Respiratory disorders other than COPD.
- Clinically significant non-respiratory diseases or abnormalities that are not adequate controlled.
- A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.
- A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition.
- Hospitalization for COPD or pneumonia within 12 weeks prior to screening.
- Subjects with lung volume reduction surgery within the 12 months prior to screening.
- Abnormal and clinically significant ECG findings at screening.
- Significantly abnormal finding from clinical chemistry or hematology, tests at screening.
- Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day.
- Regular use (prescribed every day, not for as-needed use) of short-acting bronchodilators via nebulized therapy.
- Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to screening.
- A know or suspected history of alcohol or drug abuse within 2 years prior to screening.
- Affiliation with the investigational site.
- Previous use of GSK573719, GW642444, the GSK573719/GW642444 combination or the Fluticasone Furoate/GW642444 combination.
- Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer).
Data sourced from ClinicalTrials.gov (NCT01376388). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.